19 results
8-K
EGRX
Eagle Pharmaceuticals, Inc.
29 Feb 24
Cost Associated with Exit or Disposal Activities
8:09am
to reduce the Company’s current workforce by approximately 36%. Substantially all affected employees are currently dedicated to or primarily
8-K
EX-99.1
EGRX
Eagle Pharmaceuticals, Inc.
6 Dec 22
Regulation FD Disclosure
7:31am
Issues Confronting Anesthesiology Workforce: Too much demand, not enough supplyDriven by Non-Operating Room Anesthesia casesExacerbated … 0ptAdministrative burden
CONFIDENTIAL AND INTERNAL 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 126 Workforce Solutions: New Models of Care Extended
10-QT
b0wca0j7 008
17 Feb 15
Quarterly report for transitional period
12:00am
10-K
m8x2c3i9suyx 2c5
22 Dec 14
Annual report
12:00am
10-Q
mhja2mb1zi yct
15 May 14
Quarterly report
12:00am
DRS
z4a8z7m176uyv4nkfeq9
21 Oct 13
Draft registration statement
12:00am
- Prev
- 1
- Next